These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 23782380)
1. Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Watanabe A; Chansu S; Ogawa A; Asami K; Imamura M Pediatr Int; 2013 Jun; 55(3):e56-8. PubMed ID: 23782380 [TBL] [Abstract][Full Text] [Related]
2. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion. Czyz A; Lewandowski K; Kroll R; Komarnicki M Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746 [TBL] [Abstract][Full Text] [Related]
3. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia. Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569 [TBL] [Abstract][Full Text] [Related]
4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]
5. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Ottmann OG; Pfeifer H Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223 [TBL] [Abstract][Full Text] [Related]
6. Prophylactic and preemptive therapy with dasatinib after hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Caocci G; Vacca A; Ledda A; Murgia F; Piras E; Greco M; Arras M; Atzeni S; Littera R; La Nasa G Biol Blood Marrow Transplant; 2012 Apr; 18(4):652-4. PubMed ID: 22240733 [No Abstract] [Full Text] [Related]
7. Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation. Ishida Y; Terasako K; Oshima K; Sakamoto K; Ashizawa M; Sato M; Kikuchi M; Kimura S; Nakasone H; Okuda S; Kako S; Yamazaki R; Nishida J; Kanda Y Int J Hematol; 2010 Oct; 92(3):542-6. PubMed ID: 20824399 [TBL] [Abstract][Full Text] [Related]
8. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation. Ito Y; Miyamoto T; Kamimura T; Aoki K; Henzan H; Aoki T; Shiratsuchi M; Kato K; Nagafuji K; Ogawa R; Eto T; Iwasaki H; Akashi K Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e47-54. PubMed ID: 25445469 [TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562 [TBL] [Abstract][Full Text] [Related]
10. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577 [TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with dasatinib after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia. Teng CL; Yu JT; Chen HC; Hwang WL Ann Hematol; 2013 Aug; 92(8):1137-9. PubMed ID: 23307602 [No Abstract] [Full Text] [Related]
12. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. Gruber F; Mustjoki S; Porkka K Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927 [TBL] [Abstract][Full Text] [Related]
13. Dasatinib after allogeneic stem cell transplantation in a child with Philadelphia chromosome positive acute lymphoblastic leukemia. de Castro CG; Gregianin LJ; Meneses CF; Brunetto AL Pediatr Blood Cancer; 2009 Dec; 53(6):1161. PubMed ID: 19621456 [No Abstract] [Full Text] [Related]
14. Successful treatment with imatinib-combined chemotherapy for relapsed Philadelphia-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation. IMAHASHI N; TOKUNAGA M; NISHIWAKI S; YANAGISAWA M; OZAWA Y; MIYAMURA K Rinsho Ketsueki; 2009 Nov; 50(11):1612-5. PubMed ID: 20009435 [TBL] [Abstract][Full Text] [Related]
15. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure. Sonmez M; Cobanoglu U; Ovali E; Omay SB J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422 [No Abstract] [Full Text] [Related]
16. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia]. Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651 [TBL] [Abstract][Full Text] [Related]
17. Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study. Guan F; Yang L; Chen Y; Shi J; Song X; Lai X; Lu Y; Liu L; Ouyang G; Zhao Y; Yu J; Xu Y; Lan J; Fu H; Zhao Y; Qiu X; Zhu P; Cai Z; Huang H; Luo Y Cancer; 2024 Jun; 130(12):2139-2149. PubMed ID: 38315517 [TBL] [Abstract][Full Text] [Related]
18. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review. Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532 [TBL] [Abstract][Full Text] [Related]
19. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208 [TBL] [Abstract][Full Text] [Related]
20. New approved dasatinib regimen available for clinical use. Snyder DS Expert Rev Anticancer Ther; 2009 Mar; 9(3):285-92. PubMed ID: 19275507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]